JP2024532325A - Ｔｅａｄ阻害剤の投薬レジメン - Google Patents

Ｔｅａｄ阻害剤の投薬レジメン Download PDF

Info

Publication number
JP2024532325A
JP2024532325A JP2024512986A JP2024512986A JP2024532325A JP 2024532325 A JP2024532325 A JP 2024532325A JP 2024512986 A JP2024512986 A JP 2024512986A JP 2024512986 A JP2024512986 A JP 2024512986A JP 2024532325 A JP2024532325 A JP 2024532325A
Authority
JP
Japan
Prior art keywords
cancer
tead
treatment
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532325A5 (https=
Inventor
シャポー，エミリー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024532325A publication Critical patent/JP2024532325A/ja
Publication of JP2024532325A5 publication Critical patent/JP2024532325A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024512986A 2021-09-01 2022-08-30 Ｔｅａｄ阻害剤の投薬レジメン Pending JP2024532325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163239506P 2021-09-01 2021-09-01
US63/239,506 2021-09-01
PCT/IB2022/058130 WO2023031798A1 (en) 2021-09-01 2022-08-30 Dosing regimen for a tead inhibitor

Publications (2)

Publication Number Publication Date
JP2024532325A true JP2024532325A (ja) 2024-09-05
JP2024532325A5 JP2024532325A5 (https=) 2025-09-08

Family

ID=83355146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512986A Pending JP2024532325A (ja) 2021-09-01 2022-08-30 Ｔｅａｄ阻害剤の投薬レジメン

Country Status (11)

Country Link
US (1) US20240358720A1 (https=)
EP (1) EP4395768A1 (https=)
JP (1) JP2024532325A (https=)
KR (1) KR20240055021A (https=)
CN (1) CN117835977A (https=)
AU (1) AU2022340987A1 (https=)
CA (1) CA3225444A1 (https=)
IL (1) IL309246A (https=)
MX (1) MX2024002566A (https=)
TW (1) TW202327579A (https=)
WO (1) WO2023031798A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530594A (ja) * 2015-10-15 2018-10-18 インベンティバ 新規な化合物であるｙａｐ／ｔａｚ−ｔｅａｄ相互作用阻害剤、および悪性中皮腫の治療でのその使用
WO2021186324A1 (en) * 2020-03-16 2021-09-23 Novartis Ag Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4030233B1 (en) 2019-09-18 2025-05-07 Ningbo Sunny Opotech Co., Ltd. Periscopic camera module and electronic device
CA3205726A1 (en) 2021-01-25 2022-07-28 Alfredo C. Castro Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530594A (ja) * 2015-10-15 2018-10-18 インベンティバ 新規な化合物であるｙａｐ／ｔａｚ−ｔｅａｄ相互作用阻害剤、および悪性中皮腫の治療でのその使用
WO2021186324A1 (en) * 2020-03-16 2021-09-23 Novartis Ag Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESARCH, vol. Vol. 79, Issue 13_Supplement,, JPN6026013498, 2019, pages 3086, ISSN: 0005835014 *

Also Published As

Publication number Publication date
IL309246A (en) 2024-02-01
US20240358720A1 (en) 2024-10-31
MX2024002566A (es) 2024-03-20
EP4395768A1 (en) 2024-07-10
WO2023031798A1 (en) 2023-03-09
KR20240055021A (ko) 2024-04-26
CN117835977A (zh) 2024-04-05
AU2022340987A1 (en) 2024-01-18
CA3225444A1 (en) 2023-03-09
TW202327579A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
JP6742391B2 (ja) 併用療法
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤）
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
JP7278331B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
WO2022271923A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
TWI866427B (zh) 雌激素受體降解劑之給藥方案
EA034992B1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CN107427522A (zh) 用于治疗黑素瘤的阿吡莫德
JP2024532325A (ja) Ｔｅａｄ阻害剤の投薬レジメン
CN111617081B (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
WO2014031856A1 (en) Combination therapy using pi3 kinase and braf inhibitors
TW202500147A (zh) 雌激素受體降解劑與ｃｄｋ７抑制劑之組合
WO2025229127A1 (en) A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
WO2025148858A1 (zh) FAK抑制剂和Pan-RAS抑制剂
HK40127185A (zh) 雌激素受体降解剂的给药方案
JP2024540399A (ja) Ｍｅｔ受容体チロシンキナーゼ阻害剤を含む薬物の組み合わせ及びその使用
WO2021150109A1 (en) Abt-751 and ionizing radiation
EA040191B1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407